Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.

Literature DB >> 7083450

Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.

Abstract

In order to determine if any inherent sensitivity differences may exist between VP16-213 and VM26 individual human tumors were grown in vitro and drug sensitivities were determined using the soft agar clonogenic assay method. Only nine of the 34 tumors tested so far showed a differing sensitivity to VP16-213 and VM26 as measured by a 25% or greater colony number reduction. However in none of these tumors did this added reduction result in a 70% decrease over control plate colony numbers. As yet we have been unable to demonstrate any clinically meaningful inherent in vitro sensitivity difference between VP16-213 and VM26 in any tumor type tested.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1982 PMID： 7083450 DOI： 10.1007/BF00254531

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

7 in total

1. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.

Authors: L M Allen; P J Creaven
Journal: Eur J Cancer Date: 1975-10 Impact factor: 9.162

2. Direct cloning of human ovarian carcinoma cells in agar.

Authors: A W Hamburger; S E Salmon; M B Kim; J M Trent; B J Soehnlen; D S Alberts; H J Schmidt
Journal: Cancer Res Date: 1978-10 Impact factor: 12.701

Review 3. Etoposide (VP-16-213).

Authors: B F Issell; S T Crooke
Journal: Cancer Treat Rev Date: 1979-06 Impact factor: 12.111

4. In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy.

Authors: D S Alberts; S E Samon; H S Chen; E A Surwit; B Soehnlen; L Young; T E Moon
Journal: Lancet Date: 1980-08-16 Impact factor: 79.321

5. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

Authors: S E Salmon; A W Hamburger; B Soehnlen; B G Durie; D S Alberts; T E Moon
Journal: N Engl J Med Date: 1978-06-15 Impact factor: 91.245

6. Primary bioassay of human tumor stem cells.

Authors: A W Hamburger; S E Salmon
Journal: Science Date: 1977-07-29 Impact factor: 47.728

7. Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy.

Authors: D D Von Hoff; J Casper; E Bradley; J Sandbach; D Jones; R Makuch
Journal: Am J Med Date: 1981-05 Impact factor: 4.965

7 in total

5 in total

Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.

1. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.

2. Direct cloning of human ovarian carcinoma cells in agar.

Review 3. Etoposide (VP-16-213).

4. In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy.

5. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

6. Primary bioassay of human tumor stem cells.

7. Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy.

Review 1. Current development of podophyllotoxins.

2. Chemical and biological stability of anticancer drugs used in a human tumor clonogenic assay.

3. Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents.

Review 4. The clinical pharmacology of etoposide and teniposide.

5. Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas.